All In Biotech

Drug Trial Radar · NCT03761849

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 899 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

899

Actual

Start

Jan 23, 2019

Primary completion

Mar 24, 2022

Study completion Mar 24, 2022

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)

Conditions

  • Huntingtons Disease

Interventions

  • RO7234292Drug

    Intrathecal injection

  • PlaceboDrug

    Intrathecal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) Score-Z ScoreTime frame: Weeks 21 for ODC and 69 for NDC
  2. Change From Baseline in the Total Functional Capacity (TFC) ScoreTime frame: Weeks 21 for ODC and 69 for NDC

Locations

96 sites in 18 countries. Site status is shown where the registry gives one.

  • Uab Medicine

    Birmingham, Alabama

  • Barrow Neurological Institute

    Phoenix, Arizona

  • University of California San Diego

    La Jolla, California

  • Stanford Univ Medical Center

    Palo Alto, California

  • SC3 Research Group, Inc

    Pasadena, California

  • University of California Davis Medical System

    Sacramento, California

  • CenExel Rocky Mountain Clinical Research, LLC

    Englewood, Colorado

  • Georgetown University; Research Division, Psychiatry

    Washington D.C., District of Columbia

  • University of South Florida

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • John Hopkins University School of Medicine

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Dent Neurological Institute

    Amherst, New York

  • Columbia University

    New York, New York

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • The University of Texas Health Science Center at Houston; McGovern Medical School

    Houston, Texas

  • University of Utah Clinical Neurosciences Center

    Salt Lake City, Utah

  • Evergreen Health Care Center

    Kirkland, Washington

  • Hospital Ramos Mejía

    CABA, Argentina

  • INEBA

    Capital Federal, Argentina

  • Hospital Britanico de Buenos Aires

    Ciudad Autonoma Buenos Aires, Argentina

  • WESTMEAD HOSPITAL; Deparment of Neurology

    Westmead, New South Wales, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Royal Melbourne Hospital; Department of Neurology

    Parkville, Victoria, Australia

  • Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie

    Innsbruck, Austria

  • Christian-Doppler-Klinik - Universitätsklinikum; Universitätskliniik für Neurologie

    Salzburg, Austria

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • University of British Columbia Hospital; Division of Neurology

    Vancouver, British Columbia, Canada

  • True North Clinical Research-Halifax

    Halifax, Nova Scotia, Canada

  • Centre for Movement Disorders

    North YORK, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Centre Hospitalier de l?Université de Montréal (CHUM)

    Montreal, Quebec, Canada

  • Centro de Trastornos del Movimiento (CETRAM); CETRAM

    Santiago, Chile

  • Aarhus Universitetshospital; Neurologisk Afdeling F, Neurogenetisk Afsnit

    Aarhus N, Denmark

  • Rigshospitalet, Hukommelsesklinikken

    København Ø, Denmark

  • CHU Angers, Batiement Larrey 2, Neurologie

    Angers, France

  • Hopital Henri Mondor; Service de Neurologie

    Créteil, France

  • Hopital Roger Salengro Service de Neurologie

    Lille, France

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.